Mice treated with avelumab had an increased frequency of CD8+ splenocytes specific for MC38 tumor cells as well as the p15E endogenous retroviral tumor antigen [27], as determined by the number of IFN-γ‒producing spots (Figure 2C). This evidence concerns the gene IFNG and neoplasm.